Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study

Rituximab plus chemotherapy induction followed by rituximab maintenance for up to 2 years confers a long-term benefit in terms of progression-free survival in patients with indolent non-Hodgkin lymphoma. It is not known whether further prolonged maintenance with rituximab provides additional benefit...

Descripción completa

Detalles Bibliográficos
Autores principales: Rule, Simon, Barreto, Wolney Gois, Briones, Javier, Carella, Angelo M., Casasnovas, Olivier, Pocock, Chris, Wendtner, Clemens-Martin, Zaja, Francesco, Robson, Susan, MacGregor, Lachlan, Tschopp, Roger R., Nick, Sonja, Dreyling, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804572/
https://www.ncbi.nlm.nih.gov/pubmed/34134469
http://dx.doi.org/10.3324/haematol.2020.274803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804572/
https://www.ncbi.nlm.nih.gov/pubmed/34134469
http://dx.doi.org/10.3324/haematol.2020.274803

Ejemplares similares